FY2025 EPS Estimates for Exelixis Lifted by Zacks Research

Exelixis, Inc. (NASDAQ:EXEL) – Equities researchers at Zacks Research raised their FY2025 earnings per share estimates for Exelixis in a report released on Tuesday, February 3rd. Zacks Research analyst Team now forecasts that the biotechnology company will post earnings per share of $2.65 for the year, up from their prior estimate of $2.55. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis’ Q4 2025 earnings at $0.75 EPS, Q1 2026 earnings at $0.61 EPS, Q2 2026 earnings at $0.63 EPS, Q3 2026 earnings at $0.68 EPS, Q4 2026 earnings at $0.83 EPS, FY2026 earnings at $2.76 EPS, Q1 2027 earnings at $0.76 EPS, Q2 2027 earnings at $0.91 EPS, Q3 2027 earnings at $0.92 EPS, Q4 2027 earnings at $1.07 EPS and FY2027 earnings at $3.65 EPS.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.10. The firm had revenue of $597.76 million during the quarter, compared to the consensus estimate of $590.04 million. Exelixis had a return on equity of 31.06% and a net margin of 29.63%.The firm’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.47 earnings per share.

A number of other research analysts have also weighed in on the company. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Exelixis in a report on Thursday, January 22nd. UBS Group set a $41.00 target price on Exelixis in a report on Monday, January 5th. Barclays upped their price objective on Exelixis from $41.00 to $44.00 and gave the company an “equal weight” rating in a research report on Wednesday. Oppenheimer restated a “market perform” rating and set a $36.00 target price on shares of Exelixis in a research report on Wednesday, November 5th. Finally, Wall Street Zen upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a report on Sunday, December 14th. Eleven analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $46.16.

Exelixis Price Performance

Exelixis stock opened at $42.37 on Thursday. The stock has a market capitalization of $11.36 billion, a PE ratio of 17.88, a price-to-earnings-growth ratio of 0.73 and a beta of 0.42. The business has a 50 day simple moving average of $43.69 and a 200-day simple moving average of $41.00. Exelixis has a 12 month low of $32.38 and a 12 month high of $49.62.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Farallon Capital Management LLC boosted its position in shares of Exelixis by 21.6% in the third quarter. Farallon Capital Management LLC now owns 19,501,500 shares of the biotechnology company’s stock worth $805,412,000 after buying an additional 3,466,000 shares during the period. AQR Capital Management LLC raised its holdings in shares of Exelixis by 20.7% during the third quarter. AQR Capital Management LLC now owns 9,181,359 shares of the biotechnology company’s stock worth $379,190,000 after acquiring an additional 1,575,280 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Exelixis by 0.4% during the 2nd quarter. Geode Capital Management LLC now owns 7,445,469 shares of the biotechnology company’s stock valued at $328,196,000 after buying an additional 28,289 shares during the last quarter. Invesco Ltd. lifted its stake in Exelixis by 7.1% in the third quarter. Invesco Ltd. now owns 5,960,525 shares of the biotechnology company’s stock valued at $246,170,000 after acquiring an additional 394,897 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its stake in shares of Exelixis by 42.9% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 5,262,643 shares of the biotechnology company’s stock valued at $231,951,000 after purchasing an additional 1,580,567 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Insider Transactions at Exelixis

In other news, EVP Patrick J. Haley sold 34,187 shares of the firm’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $41.88, for a total transaction of $1,431,751.56. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Dana Aftab sold 48,383 shares of the firm’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $42.50, for a total transaction of $2,056,277.50. Following the transaction, the executive vice president owned 664,778 shares in the company, valued at $28,253,065. This represents a 6.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 245,235 shares of company stock worth $10,490,600. 2.82% of the stock is currently owned by corporate insiders.

Key Stories Impacting Exelixis

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Zacks Research raised multiple quarterly and full-year EPS forecasts for Exelixis, lifting FY2026 to $2.76 (from $2.34) and FY2027 to $3.65 (from $3.30) and raising several Q1–Q4 quarterly estimates — a broad upward revision that signals improving analyst expectations for revenue and profit growth. Zacks / MarketBeat Coverage
• Positive Sentiment: Zacks published a bullish piece (“3 Reasons Why Growth Investors Shouldn’t Overlook Exelixis”) highlighting the company’s growth attributes and catalysts that could drive outperformance versus the market. This type of coverage can attract growth-focused investors. 3 Reasons Why Growth Investors Shouldn’t Overlook Exelixis (Zacks)
• Positive Sentiment: Another Zacks feature ranks Exelixis as a top growth stock using its Style Scores — positive signal for momentum and style-driven fund flows that may support demand for the shares. Exelixis is a Top-Ranked Growth Stock (Zacks)
• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating on EXEL, providing another institutional vote of confidence that may support investor sentiment and buying interest. HC Wainwright Reaffirms “Buy” Rating (American Banking News)

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.